Saturday, October 20, 2012

CSX Earnings


            CSX Corporation released earnings for Q3 2012 on October 16th. They reported a net income of $455 million vs $464 million in Q3 2011, showing a decline of 1.9% year-over-year. This breaks a four-quarter streak of profit increases. A mild winter caused coal demand to be suppressed; coal composes more than a fourth of the revenue for CSX. International volume of the company grew 10%, in part due to the success of the Maersk business. The reported EPS was $.44, beating consensus marginally, which was $.43, and outperforming Q3 2011 earnings of $.43. Reported revenues were $2.89 billion, missing expectations set at $2.93 billion. Shares of CSX were down 2.2% in the afternoon sharing at $21.15.

            Looking forward, the company sees itself as a neutral outlook for the fourth quarter. Estimated EPS for Q4 is $.47, and estimates are $1.85 for the fiscal year. Coal will continue to be challenged by low gas prices and high utility stockpiles, but the industrial, agricultural, construction, and domestic sectors all have favorable outlooks. There is uncertainty going forward with the company for Q4, as coal is becoming less demanded and CSX could be looking at moderate labor inflation. CSX sees itself with only moderate growth for the future.

- Peter Rodrigues, Industrial Junior Analyst

Alexion Pharmaceutical dips 5.32%

At Fridays close Alexion Pharmaceuticals (ticker: ALXN) ended the day 5.32% on approximately double its average trading volume. Although the reason for this fall isn't due to a company-specific event, we can attribute this to what has been a weak earnings season. With ALXN due to report Q3 earnings on October 24th, investors may be speculating a ALXN miss. In addition, despite not having any direct competitors, Cubist Pharmaceuticals (ticker: CBST), another niche market biotech player, traded down on lower than expected revenue estimates. While many are uncertain, we remain positive on ALXN's ability to continue to "beat and raise" estimates.

CSX Earnings



CSX Corporation released earnings for Q3 2012 on October 16th. They reported a net income of $455 million vs $464 million in Q3 2011, showing a decline of 1.9% year-over-year. This breaks a four-quarter streak of profit increases. A mild winter caused coal demand to be suppressed; coal composes more than a fourth of the revenue for CSX. International volume of the company grew 10%, in part due to the success of the Maersk business. The reported EPS was $.44, beating consensus marginally, which was $.43, and outperforming Q3 2011 earnings of $.43. Reported revenues were $2.89 billion, missing expectations set at $2.93 billion. Shares of CSX were down 2.2% in the afternoon sharing at $21.15.

            Looking forward, the company sees itself as a neutral outlook for the fourth quarter. Estimated EPS for Q4 is $.47, and estimates are $1.85 for the fiscal year. Coal will continue to be challenged by low gas prices and high utility stockpiles, but the industrial, agricultural, construction, and domestic sectors all have favorable outlooks. There is uncertainty going forward with the company for Q4, as coal is becoming less demanded and CSX could be looking at moderate labor inflation. CSX sees itself with only moderate growth for the future.

-Peter Rodrigues, Industrial Junior Analyst

Friday, October 19, 2012

Honeywell (HON) Q3 earnings release


Honeywell came out with a good quarter in beating analysts’ estimates for a fifth quarter in a row. Having an increase in EPS of 9% to $1.20 from $1.10 it blew past estimates of 1.14 for the company. Sales for the company as a whole had a pretty shallow growth of 2% to 9.34 billion which were below estimates, but with a segment profit increase of 8% with a margin percentage increase of 110 basis points. With Net Income having a 10% increase from $862M in Q3 2011 to $920M in Q3 2012 the company has proven its investments in new products and high growth regions, such as natural gas, and a balanced mix of long- and short-term business cycles was able to offset their European weaknesses, lower demand for short-cycle products in China and the U.S., and foreign exchange headwinds in the future.  Also stating a sense of confidence with maintaining a strong backlog with new platform wins across many of their different sectors.
Their guidance for sales and EPS were a little mixed, having lowered and narrowed their sales guidance outlook by 3% versus 2011 with a drop from $37.8-38.4B to $37.5-37.7B. However, they narrowed and increased their EPS guidance by 10% versus 2011 from $4.40-$4.55 to $4.45-4.50.

Following the earnings release, stock price closed today $62.49, a growth of 1.74% breaking through the $62.00 ceiling that seemed to be a resistance point for the year.   Following their acquisition Thomas Russell in their UOP segment, CEO Dave Cote placed a strong emphasis on natural gas investment which seems to be the way with the future outlook of coal depleting.

Different sectors: Q4 2012 outlook (primary causes)

Aerospace- 0%-(2)% reduction because of defense program ramp downs.

Automation and Controls Solution- 1%-3% growth because of increased investments for growth and   productivity yielding strong sales conversion.

Performance Materials and Technologies- 4%-6% growth because of UOP acquisition of Thomas Russell in the natural gas sector.

Transportation- (8)%-(12)% reductions because of EU light vehicle production down (–9%)

Honeywell Overall-
0%-1% ; Total $9.4-$9.6B      

Baxter International (BAX) Q3 Earnings Release

Baxter International released Q3 earnings this past Thursday, 10/18. 

Full year EPS guidance was narrowed as management trimmed off the top and increased the bottom of FY EPS expectations. They now expect FY$4.51-$4.54 a share, versus $4.49-$4.57. This will represent an increase of ~15% versus 2011. For Q3, BAX brought in an adjusted EPS of $1.14 per diluted share, a slight increase of 5% from Q3 2011. Management expects Q4 EPS to fall within $1.24 to $1.27. This falls within analyst expectations of $1.26 per share from $3.71 Billion in revenue. 

Total revenues for the quarter were $3.5 billion, near flat with Q3 2011.
• Global Bioscience: $1.5 Billion (+5% vs 2011) 
• Medical products: $2 Billion (0% vs. 2011) 

Gross margin improved to 52.1%, the strongest it has been in 3 years. Expectations are that it will continue to grow for full year. 

Net income rose to $583 Million from $573 Million last year. 

Management guidance for full year 2012 was largely conservative at a 5% growth rate, however they predict that macro effects and exchange rate issues will erode that to roughly 2%. Moving forward, BAX wants to continue to leverage their current product portfolio in new markets while trying to expand into “unmet medical needs. “

Following Q3 earnings, BAX shares rose above our price target of 61.90 to close at $62.08. Because of the price target being met, the model will be revised for a new target price and thesis by next Monday

Thursday, October 18, 2012

BlackRock (BLK) Q3 Earnings Release


BlackRock reported Q3 2012 earnings of $3.65 per share, this beat consensus estimates of analysts that projected $3.32. BlackRock had several key themes throughout the quarter that drove the beat. Assets under management (AUM) grew to $3.673 Trillion; a 10% improvement over the same period ended a year prior. Also, contributing to strong revenue during the quarter were iShares posting the strongest quarter of inflows since 2009.  This included notable inflows into equity ETFs, not seen for some time. 
Revenue had a strong quarter improving 4% from Q2 2012, but expense management was a main highlight for BlackRock during the Q3. BlackRock’s operating margin improved to 37.7% a substantial increase over Q3 of 2011, which had a 34.9% operating margin.

BlackRock completed its acquisition of Swiss Re Private Equity Partners during September, which contributed the AUM improvement. Management decided to repurchase 960,100 shares during the quarter (8.2 million YTD), which was expected.

Earnings call discussion included the continued theme of price competition in the industry, following BlackRock’s disclosure earlier in the week that iShares ETF fees will be lowered to response to market pressure. This pressure mainly comes from competitor, Vangaurd. Our expectations regarding lower fees on ETFs is that improved AUM will offset the losses in the medium term.  Going forward BlackRock expects competitors to raise their fees modestly because they are barely breaking even on their products. BlackRock will launch TV advertisements for the first time to help combat growing competition; we expect this strategy to be successful and representative of BlackRock’s already strong brand position.

How our estimates compared: Revenue was inline with our expectations. Expenses were slightly under by 1%. Net income was 15% above our expectations, due to a favorable tax rate on the quarter. Diluted EPS beat our estimates by 16%; we projected EPS of $3.14 vs. $ 3.65 actual. We are currently projecting EPS of $3.42 for Q4 and EPS of $13.30 for Full Year 2012.

Looking forward we expect AUM inflows to be strong during Q4, paying special attention to iShares fee changes and how margins are impacted in that segment going forward. 

Wednesday, October 17, 2012

RS Sell Thesis

Today we sold all of our 90 shares of Reliance Steel (RS) at the price of $53.52. This represents a loss of 3.85%. The company continues to do well, but it is not reflective in their stock price. This is a great example of a great company, but a bad stock. We bought in at the tail end of a 40% upswing and the stock plateaued after we bought it. The thesis when we originally bought this stock was based on improving steel demand and steel pricing. While this thesis held true for a few months, it turned for the worse and the steel industry as a whole suffered. The steel industry currently is not doing well due to a very high supply, but weakening  demand. This is driving prices down which is hurting all companies throughout the industry. A big driver of the industry is China because they have a very high demand for steel. With their economy currently slowing, it is hurting the steel industry as whole, even companies with minimal exposure such as Reliance Steel. RS has beat estimates for the first and second quarters of this year, but in the last conference call, management lowered guidance for the second half of the year, which was slightly below the streets estimates. So I felt as if this was a good time to sell out with minimal losses. The stock usually does better in the first two quarters and then regresses. If the stock becomes favorable again at a lower price before the first quarter of 2013, it may be a good opportunity to buy back in.

-John Astarita